TGF-β1 as a therapeutic target for pulmonary fibrosis and COPD

Expert Review of Clinical Pharmacology

Volumn 1, Issue 4, 2008, Pages 547-558

  Kang, Hye Ryun ^a   Lee, Jae Young ^b   Lee, Chun Geun ^b  

^a Hallym University   (South Korea)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Emphysema; Pulmonary fibrosis; Stem cells; TGf ; Therapeutic target

Indexed keywords

ACETYLCYSTEINE; APOPTOSIS INHIBITOR; CONNECTIVE TISSUE GROWTH FACTOR; DECORIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; SEMAPHORIN; SEMAPHORIN 7A; SMAD3 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE CONTROL; HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; LUNG ALVEOLUS; LUNG EMPHYSEMA; LUNG FIBROSIS; MACROPHAGE ACTIVATION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TH1 CELL; TH2 CELL;

EID: 49449094115     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.4.547     Document Type: Review

References (118)

1. Dennler S, Goumans MJ, ten Dijke P. Transforming growth factor β signal transduction. J. Leukoc. Biol. 71(5), 731-740 (2002).
2. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu. Rev. Immunol. 16, 137-161 (1998).
3. Attisano L, Wrana JL. Signal transduction by members of the transforming growth factor-β superfamily. Cytokine Growth Factor Rev. 7(4), 327-339 (1996).
4. Massague J. How cells read TGF-β signals. Nat. Rev. Mol. Cell Biol. 1(3), 169-178 (2000).
5. Feng XH, Derynck R. Specificity and versatility in TGF-β signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659-693 (2005).
6. Letterio JJ, Roberts AB. Transforming growth factor-β1-deficient mice: identification of isoform-specific activities in vivo. J. Leukoc. Biol. 59(6), 769-774 (1996).
7. Lee CG, Cho SJ, Kang MJ et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor β1-induced pulmonary fibrosis. J. Exp. Med. 200(3), 377-389 (2004).
8. Raghu G. Interstitial lung disease: a clinical overview and general approach. In: Fishman's Pulmonary Diseases and Disorders. Fishman AP, Elias JA, Fishman JA et al. (Eds). McGraw-Hill Inc., NY, USA 1037-1053 (1998).
9. Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350(26), 2645-2653 (2004).
10. Fabbri LM, Romagnoli M, Corbetta L et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 167(3), 418-424 (2003).
11. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 118(5), 1278-1285 (2000).
12. Faulkner MA, Hilleman DE. The economic impact of chronic obstructive pulmonary disease. Expert Opin. Pharmacother. 3(3), 219-228 (2002).
13. Vermeire P. The burden of chronic obstructive pulmonary disease. Respir. Med. 96(Suppl. C), S3-S10 (2002).
14. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367(9524), 1747-1757 (2006).
15. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370(9589), 765-773 (2007).
16. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N. Engl. J. Med. 350(26), 2689-2697 (2004).
17. Senior RM. Chronic obstructive pulmonary disease: epidemiology, pathophysiology, pathogenesis, clinical course management and rehabilitation. In: Fishman's Manual of Pulmonary Diseases and Disorders. Fishman AP (Ed.). McGraw-Hill Inc., NY, USA 118-142 (2002).
18. Senior RM, Shapiro SD. Chronic obstructive pulmonary disease: epidemiology, pathophysiology, and pathogenesis. In: Fishman's Pulmonary Diseases and Disorders. Fishman AP, Elias JA, Fishman JA et al. (Eds). McGraw-Hill Inc., NY, USA 659-681 (1998).
19. Panettieri RA, Fishman AP. Chronic obstructive lung disease: overview. In: Fishman's Manual of Pulmonary Diseases and Disorders. Fishman AP (Ed.). McGraw-Hill Inc., NY, USA 105-117 (2002).
20. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J. Clin. Invest. 104(8), 1001-1006 (1999).
21. Hansen PR, Holm AM, Svendseri UG, Olsen PS, Andersen CB. Apoptosis and formation of peroxynitrite in the lungs of patients with obliterative bronchiolitis. J. Heart Lung Transplant. 19(2), 160-166 (2000).
22. Vlahovic G, Russell ML, Mercer RR, Crapo JD. Cellular and connective tissue changes in alveolar septal walls in emphysema. Am. J. Respir. Crit. Care Med. 160(6), 2086-2092 (1999).
23. Tuder RM, Zhen L, Cho CY et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am. J. Respir. Cell Mol. Biol. 29(1), 88-97 (2003).
24. MacNee W, Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol. Med. 7(2), 55-62 (2001).
25. Kasahara Y, Tuder RM, Taraseviciene-Stewart L et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Invest. 106(11), 1311-1319 (2000).
26. Kasahara Y, Tuder RM, Cool CD et al. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am. J. Respir. Crit. Care Med. 163(3 Pt 1), 737-744 (2001).
27. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am. J. Respir. Cell Mol. Biol. 28(5), 555-562 (2003).
28. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur. Respir. J. 17(5), 946-953 (2001).
29. Segura-Valdez L, Pardo A, Gaxiola M et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 117(3), 684-694 (2000).
30. Yokohori N, Aoshiba K, Nagai A. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 125(2), 626-632 (2004).
31. Tuder RM, Petrache I, Elias JA, Voelkel NF, Henson PM. Apoptosis and emphysema: the missing link. Am. J. Respir. Cell Mol. Biol. 28(5), 551-554 (2003).
32. Zheng T, Kang MJ, Crothers K et al. Role of cathepsin S-depenaent epithelial cell apoptosis in γ interferon-induced alveolar remodeling and pulmonary emphysema. J. Immunol. (2005) (In Press).
33. Takizawa H, Tanaka M, Takami K et al. Increased expression of transforming growth factor-β1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 163(6), 1476-1483 (2001).
34. Kokturk N, Tatlicioglu T, Memis L, Akyurek N, Akyol G. Expression of transforming growth factor β1 in bronchial biopsies in asthma and COPD. J. Asthma 40(8), 887-893 (2003).
35. Neptune ER, Frischmeyer PA, Arking DE et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33(3), 407-411 (2003).
36. Springer J, Scholz FR, Peiser C, Groneberg DA, Fischer A. SMAD-signaling in chronic obstructive pulmonary disease: transcriptional down-regulation of inhibitory SMAD 6 and 7 by cigarette smoke. Biol. Chem. 385(7), 649-653 (2004).
37. Morris DG, Huang X, Kaminski N et al. Loss of integrin α(v)β6-mediated TGF-β activation causes MMP12-dependent emphysema. Nature 422(6928), 169-173 (2003).
38. Bonniaud P, Kolb M, Galt T et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-β-mediated pulmonary fibrosis. J. Immunol. 173(3), 2099-2108 (2004).
39. Wu L, Chau J, Young RP et al. Transforming growth factor-β1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax 59 (2), 126-129 (2004).
40. Kang HR, Lee CG, Homer RJ, Elias JA. Semaphorin 7A plays a critical role in TGF-β1-induced pulmonary fibrosis. J. Exp. Med. 204(5), 1083-1093 (2007).
41. Kang HR, Cho SJ, Lee CG, Homer RJ, Elias JA. Transforming growth factor (TGF)-β1 stimulates pulmonary fibrosis and inflammation via a Bax-dependent, bid-activated pathway that involves matrix metalloproteinase-12. J. Biol. Chem. 282(10), 7723-7732 (2007).
42. Yamasaki M, Kang HR, Homer RJ et al. P21 regulates TGF-β1-induced pulmonary responses via a TNF-α-signaling pathway. Am. J. Respir. Cell Mol. Biol. 38(3), 346-353 (2008).
43. Krein PM, Winston BW. Roles for insulin-like growth factor I and transforming growth factor-β in fibrotic lung disease. Chest 122(6 Suppl.), 289S-293S (2002).
44. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134(2), 136-151 (2001).
45. Khalil N, O'Connor RN, Flanders KC, Unruh H. TGF-β 1, but not TGF-β 2 or TGF-β 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am. J. Respir. Cell Mol. Biol. 14(2), 131-138 (1996).
46. Khalil N, Parekh TV, O'Connor R et al. Regulation of the effects of TGF-β 1 by activation of latent TGF-β 1 and differential expression of TGF-β receptors (T β R-I and T β R-II) in idiopathic pulmonary fibrosis. Thorax 56(12), 907-915 (2001).
47. Xu YD, Hua J, Mui A et al. Release of biologically active TGF-(β) 1 by alveolar epithelial cells results in pulmonary fibrosis. Am. J. Physiol. (Lung Cell Mol. Physiol.) (2003) (In press).
48. Yehualaeshet T, O'Connor R, Begleiter A et al. A CD36 synthetic peptide inhibits bleomycin-induced pulmonary inflammation and connective tissue synthesis in the rat. Am. J. Respir. Cell Mol. Biol. 23(2), 204-212 (2000).
49. Nakao A, Fujii M, Matsumura R et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induccd lung fibrosis in mice. J. Clin. Invest. 104(1), 5-11 (1999).
50. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. 100(4), 768-776 (1997).
51. Kelly M, Kolb M, Bonniaud P, Gauldie J. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr. Pharm. Des. 9(1), 39-49 (2003).
52. Kuwano Y, Maeyama T, Inoshima I et al. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases. Respirology 7(1), 15-21 (2002).
53. Kuwano K, Miyazaki H, Hagimoto N et al. The involvement of Fas-Fas ligand pathway in fibrosing lung diseases. Am. J. Respir. Cell Mol. Biol. 20(1), 53-60 (1999).
54. Kuwano K, Kunitake R, Kawasaki M et al. P21 Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 154(2 Pt 1), 477-483 (1996).
55. Kuwano K, Hagimoto N, Kawasaki M et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J. Clin. Invest. 104(1), 13-19 (1999).
56. Ling E, Robinson DS. Transforming growth factor-β1: its anti-inflammatory and pro-fibrotic effects. Clin. Exp. Allergy 32(2), 175-178 (2002).
57. Flanders KC, Sullivan CD, Fujii M et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am. J. Pathol. 160(3), 1057-1068 (2002).
58. Akhurst RJ, Derynck R. TGF-β signaling in cancer - a double-edged sword. Trends Cell Biol. 11 (11), S44-S51 (2001).
59. Roberts AB, Piek E, Bottinger EP et al. Is Smad3 a major player in signal transduction pathways leading to fibrogenesis? Chest 120(1 Suppl.), 43S-47S (2001).
60. Fargeas C, Wu CY, Nakajima T et al. Differential effect of transforming growth factor β on the synthesis of Th1- and Th2-like lymphokines by human T lymphocytes. Eur. J. Immunol. 22(8), 2173-2176 (1992).
61. Zhang X, Giangreco L, Broome HE, Dargan CM, Swain SL. Control of CD4 effector fate: transforming growth factor β1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J. Exp. Med. 182(3), 699-709 (1995).
62. Lee CG, Homer RJ, Zhu Z et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β(1). J. Exp. Med. 194(6), 809-821 (2001).
63. Martin M, Lefaix J, Delanian S. TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target? Int. J. Radiat. Oncol. Biol. Phys. 47(2), 277-290 (2000).
64. Kalluri R, Sukhatme VP. Fibrosis and angiogenesis. Curr. Opin. Nephrol. Hypertens. 9(4), 413-418 (2000).
65. Pittet JF, Griffiths MJ, Geiser T et al. TGF-β is a critical mediator of acute lung injury. J. Clin. Invest. 107(12), 1537-1544 (2001).
66. Fukuda H, Motohiro T, Nakai K et al. Negative effect of transforming growth factor-β-1 on intestinal anastomotic tissue regeneration. Eur. Surg. Res. 33(5-6), 388-394 (2001).
67. Chan T, Ghahary A, Demare J et al. Development, characterization, and wound healing of the keratin 14 promoted transforming growth factor-β1 transgenic mouse. Wound Repair Regen. 10(3), 177-187 (2002).
68. Amendt C, Mann A, Schirmacher P, Blessing M. Resistance of keratinocytes to TGFβ-mediated growth restriction and apoptosis induction accelerates re-epithelialization in skin wounds. J. Cell Sci. 115(Pt 10), 2189-2198 (2002).
69. Wynn TA. Fibrotic disease and the T(H) 1/T(H) 2 paradigm. Nat. Rev. Immunol. 4(8), 583-594 (2004).
70. Kaviratne M, Hesse M, Leusink M et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-β independent. J. Immunol. 173(6), 4020-4029 (2004).
71. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol. Rev. 84(3), 731-765 (2004).
72. Guerassimov A, Hoshino Y, Takubo Y et al. The development of emphysema in cigarette smoke exposed mice is strain dependent. Am. J. Respir. Crit. Care Med. 170(9), 974-980 (2004).
73. Kolb M, Bonniaud P, Galt T et al. Differences in the fibrogenic response after transfer of active transforming growth factor-β1 gene to lungs of 'fibrosis-prone' and 'fibrosis-resistant' mouse strains. Am. J. Respir. Cell Mol. Biol. 27(2), 141-150 (2002).
74. Haston CK, Amos CI, King TM, Travis EL. Inheritance of susceptibility to bleomycin-induced pulmonary fibrosis in the mouse. Cancer Res. 56(11), 2596-2601 (1996).
75. Haston CK, Wang M, Dejournett RE et al. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum. Mol. Genet. 11(16), 1855-1863 (2002).
76. Haston CK, Zhou X, Gumbiner-Russo L et al. Universal and fadiation-specific loci influence murine susceptibility to radiation-induced pulmonary fibrosis. Cancer Res. 62(13), 3782-3788 (2002).
77. Barth RK, Hanchett LA, Baecher-Allan CM. Mapping susceptibility genes for the induction of pulmonary fibrosis in mice. Chest 121 (3 Suppl.), 21S (2002).
78. Niewoehner DE, Hoidal JR. Lung fibrosis and emphysema: divergent responses to a common injury? Science 217(4557), 359-360 (1982).
79. Hagimoto N, Kuwano K, Hara N. [The roles of apoptosis in lung injury]. Nihon Kokyuki Gakkai Zasshi 40(5), 343-349 (2002).
80. Hagimoto N, Kuwano Y, Inoshima I et al. TGF-β 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J. Immunol. 168(12), 6470-6478 (2002).
81. Makinde T, Murphy RF, Agrawal DK. The regulatory role of TGF-β in airway remodeling in asthma. Immunol. Cell Biol. 85(5), 348-356 (2007).
82. Budinger GR, Mutlu GM, Eisenbart J et al. Proapoptotic bid is required for pulmonary fibrosis. Proc. Natl Acad. Sci. USA 103(12), 4604-4609 (2006).
83. Gazdhar A, Fachinger P, van Leer C et al. Gene transfer ofhepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. Am. J Physiol. Lung Cell. Mol. Physiol. 292(2), L529-L536 (2007).
84. Marchand-Adam S, Fabre A, Mailleux AA et al. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis. Am J. Respir. Crit. Care Med. 174(1), 58-66 (2006).
85. Lee CG, Kang HR, Homer RJ, Chupp, G, Elias JA. Transgenic modeling of transforming growth factor-β(1): role of apoptosis in fibrosis and alveolar remodeling. Proc. Am. Thorac Soc. 3(5), 418-423 (2006).
86. Molteni A, Wolfe LF, Ward WF et al. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-β (TGF-β) and α-actomyosin (α SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr. Pharm. Des. 13(13), 1307-1316 (2007).
87. Ferrari G, Pintucci G, Seghezzi G et al. VEGF, a prosurvival factor, acts in concert with TGF-β1 to induce endothelial cell apoptosis. Proc. Natl Acad. Sci. USA 103(46), 17260-17265 (2006).
88. Maharaj AS, Wilshe TE, Saint-Geniez M et al. VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma. J. Exp. Med. 205(2), 491-501 (2008).
89. Ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 11 (1), 79-89 (2008).
90. Wynn TA. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214(2), 199-210 (2008).
91. Elias JA, Lee CG, Zheng T et al. New insights into the pathogenesis of asthma. J. Clin. Invest. 111(3), 291-297 (2003).
92. Das A, Griswold D, Molloy C, Protter A, Laurent G. Fighting pulmonary fibrosis: new science brings new therapeutic opptunities. Drug Discov. Today Ther. Strateg. 1(3), 361-368 (2004).
93. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr. Rheumatol. Rep. 8(2), 145-150 (2006).
94. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab. Invest. 87(9), 858-870 (2007).
95. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J. Immunol. 171(1), 380-389 (2003).
96. Nawshad A, Lagamba D, Polad A, Hay ED. Transforming growth factor-β signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 1790-2), 11-23 (2005).
97. Kim KK, Kugler MC, Wolters PJ et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl Acad. Sci. USA 103(35), 13180-13185 (2006).
98. Willis BC, Borok Z. TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. Am. J. Physiol Lung Cell. Mol. Physiol. 293(3), L525-534 (2007).
99. Yang J, Dai C, Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J. Am. Soc. Nephrol. 16(1), 69-78 (2005).
100. Zeisberg M, Shah AA, Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J. Biol. Chem. 280(9), 8094-8100 (2005).
101. Chua F, Laurent GJ. Neutrophil elastase: mediator of extracellular matrix destruction and accumulation. Proc. Am. Thorac Soc. 3(5), 424-427 (2006).
102. Koli K, Myllarniemi M, Keski-Oja J, Kinnula VL. Transforming growth factor-β activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid. Redox Signal. 10(2), 333-342 (2008).
103. Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N. Engl. J. Med. 353(21), 2285-2287 (2005).
104. Bhatr N, Baran CP, Allen J, Magro C, Marsh CB. Promising pharmacologic innovations in treating pulmonary fibrosis. Curr. Opin. Pharmacol. 6(3), 284-292 (2006).
105. Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev. 14(6), 537-550 (2003).
106. Ask K, Martin GE, Kolb M, Gauldie J. Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. Proc. Am. Thorac Soc. 3(4), 389-393 (2006).
107. Zhang A, Wang MH, Dong Z, Yang T. Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. Am. J. Physiol. Renal Physiol. 291(6), F1323-F1331 (2006).
108. Sandulache VC, Parekh A, Li-Korotky H, Dohar JE, Hebda PA. Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-β1-induced collagen synthesis. Wound Repair Regen. 15(1), 122-133 (2007).
109. Dunkern TR, Feurstein D, Rossi GA. Sabatini F, Hatzelmann A. Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur. J. Pharmacol. 572(1), 12-22 (2007).
110. Shim YM, Zhu Z, Zheng T et al. Role of 5-lipoxygenase in IL-13-induced pulmonary inflammation and remodeling. J. Immunol. 177(3), 1918-1924 (2006).
111. Kolb M, Margetts PJ, Galt T et al. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am. J. Respir. Crit. Care Med. 163(3 Pt 1), 770-777 (2001).
112. Wipff PJ, Hinz B. Integrins and the activation of latent transforming growth factor β1 - an intimate relationship. Eur. J. Cell Biol. (2008) (Epub ahead of print).
113. Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm. Res. 24(5), 819-841 (2007).
114. Ishizawa K, Kubo H, Yamada M et al. Bone marrow-derived cells contribute to lung regeneration after elastase-induced pulmonary emphysema. FEBS Lett. 556(1-3), 249-252 (2004).
115. Krause DS, Theise ND, Collector MI et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105 (3), 369-377 (2001).
116. Yamada M, Kubo H, Kobayashi S et al. Bone marrow-derived progenitor cells are important for lung repair after lipopolysaccharide-induced lung injury. J. Immunol. 172(2), 1266-1272 (2004).
117. Rojas M, Xu J, Woods CR et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am. J. Respir. Cell Mol. Biol. 33(2), 145-152 (2005).
118. Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc. Natl Acad. Sci. USA 100(14), 8407-8411 (2003).